Opko Health (OPK) : Geduld E E scooped up 35,000 additional shares in Opko Health during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 95,000 shares of Opko Health which is valued at $954,750.Opko Health makes up approximately 1.32% of Geduld E E’s portfolio.
Other Hedge Funds, Including , Moors Cabot boosted its stake in OPK in the latest quarter, The investment management firm added 1,350 additional shares and now holds a total of 61,100 shares of Opko Health which is valued at $614,055. Opko Health makes up approx 0.10% of Moors Cabot’s portfolio.Rfg Advisory Group reduced its stake in OPK by selling 3,550 shares or 26.1% in the most recent quarter. The Hedge Fund company now holds 10,052 shares of OPK which is valued at $100,319. Opko Health makes up approx 0.09% of Rfg Advisory Group’s portfolio. First Quadrant L Pca sold out all of its stake in OPK during the most recent quarter. The investment firm sold 9,400 shares of OPK which is valued $93,342.
Opko Health opened for trading at $10.1 and hit $10.1 on the upside on Monday, eventually ending the session at $10.08, with a gain of 0.20% or 0.02 points. The heightened volatility saw the trading volume jump to 19,73,712 shares. Company has a market cap of $5,548 M.
On the company’s financial health, Opko Health reported $0.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 8, 2016. Analyst had a consensus of $-0.03. The company had revenue of $357.10 million for the quarter, compared to analysts expectations of $324.11 million. The company’s revenue was up 742.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.09 EPS.
Many Wall Street Analysts have commented on Opko Health. Company shares were Reiterated by Standpoint Research on Jun 21, 2016 to “Buy”, Firm has raised the Price Target to $ 18 from a previous price target of $16 .Standpoint Research Initiated Opko Health on Jun 3, 2016 to “Buy”, Price Target of the shares are set at $16.
OPKO Health Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose treat and prevent various conditions including point-of-care tests laboratory developed tests (LDTs) molecular diagnostics tests and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile Spain Mexico Israel Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.